These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 31096151)
1. Development and future prospects of selective organometallic compounds as anticancer drug candidates exhibiting novel modes of action. Parveen S; Arjmand F; Tabassum S Eur J Med Chem; 2019 Aug; 175():269-286. PubMed ID: 31096151 [TBL] [Abstract][Full Text] [Related]
2. Tracking antitumor metallodrugs: promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds. Morais TS; Valente A; Tomaz AI; Marques F; Garcia MH Future Med Chem; 2016 Apr; 8(5):527-44. PubMed ID: 27096164 [TBL] [Abstract][Full Text] [Related]
3. Design of Ru-arene Complexes for Antitumor Drugs. Su W; Li Y; Li P Mini Rev Med Chem; 2018; 18(2):184-193. PubMed ID: 28494728 [TBL] [Abstract][Full Text] [Related]
5. Group 9 organometallic compounds for therapeutic and bioanalytical applications. Ma DL; Chan DS; Leung CH Acc Chem Res; 2014 Dec; 47(12):3614-31. PubMed ID: 25369127 [TBL] [Abstract][Full Text] [Related]
6. Dual-targeting organometallic ruthenium(II) anticancer complexes bearing EGFR-inhibiting 4-anilinoquinazoline ligands. Zhang Y; Zheng W; Luo Q; Zhao Y; Zhang E; Liu S; Wang F Dalton Trans; 2015 Aug; 44(29):13100-11. PubMed ID: 26106875 [TBL] [Abstract][Full Text] [Related]
7. Polynuclear ruthenium, osmium and gold complexes. The quest for innovative anticancer chemotherapeutics. Hartinger CG; Phillips AD; Nazarov AA Curr Top Med Chem; 2011; 11(21):2688-702. PubMed ID: 22039871 [TBL] [Abstract][Full Text] [Related]
8. Bioanalytical and biophysical techniques for the elucidation of the mode of action of metal-based drugs. Groessl M; Dyson PJ Curr Top Med Chem; 2011; 11(21):2632-46. PubMed ID: 22039868 [TBL] [Abstract][Full Text] [Related]
9. Half-sandwich Ru II[9]aneS3 complexes structurally similar to antitumor-active organometallic piano-stool compounds: preparation, structural characterization and in vitro cytotoxic activity. Bratsos I; Jedner S; Bergamo A; Sava G; Gianferrara T; Zangrando E; Alessio E J Inorg Biochem; 2008; 102(5-6):1120-33. PubMed ID: 18279961 [TBL] [Abstract][Full Text] [Related]
10. Transferrin serves as a mediator to deliver organometallic ruthenium(II) anticancer complexes into cells. Guo W; Zheng W; Luo Q; Li X; Zhao Y; Xiong S; Wang F Inorg Chem; 2013 May; 52(9):5328-38. PubMed ID: 23586415 [TBL] [Abstract][Full Text] [Related]
11. Ruthenium(II)/(III) complexes of 4-hydroxy-pyridine-2,6-dicarboxylic acid with PPh3/AsPh3 as co-ligand: impact of oxidation state and co-ligands on anticancer activity in vitro. Kamatchi TS; Chitrapriya N; Lee H; Fronczek CF; Fronczek FR; Natarajan K Dalton Trans; 2012 Feb; 41(7):2066-77. PubMed ID: 22183160 [TBL] [Abstract][Full Text] [Related]
15. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity. Brabec V; Nováková O Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363 [TBL] [Abstract][Full Text] [Related]
16. Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents. Peacock AF; Sadler PJ Chem Asian J; 2008 Nov; 3(11):1890-9. PubMed ID: 18712745 [TBL] [Abstract][Full Text] [Related]
17. Cyclometalated Complexes of Platinum and Gold with Biological Properties: State-of-the-Art and Future Perspectives. Jurgens S; Kuhn FE; Casini A Curr Med Chem; 2018 Feb; 25(4):437-461. PubMed ID: 28554319 [TBL] [Abstract][Full Text] [Related]
19. Medicinal Chemistry of Gold Anticancer Metallodrugs. Casini A; Sun RW; Ott I Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394026 [TBL] [Abstract][Full Text] [Related]
20. Organometallic compounds in cancer therapy: past lessons and future directions. Martins P; Marques M; Coito L; Pombeiro AJ; Baptista PV; Fernandes AR Anticancer Agents Med Chem; 2014; 14(9):1199-212. PubMed ID: 25173559 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]